Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1147

Similar articles for PubMed (Select 19335322)

1.

Progression of chronic obstructive pulmonary disease: impact of inflammation, comorbidities and therapeutic intervention.

Stockley RA.

Curr Med Res Opin. 2009 May;25(5):1235-45. doi: 10.1185/03007990902868971 . Review.

PMID:
19335322
2.

[PROINFLAMMATORY CYTOKINES IN COMBINATION OF CORONARY HEART DISEASE AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE].

Provotorov VM, Budnevsky AV, Semenkova GG, Shishkina ES.

Klin Med (Mosk). 2015;93(2):5-9. Russian.

PMID:
26117912
3.

Objectively identified comorbidities in chronic obstructive pulmonary disease: impact on pulmonary rehabilitation outcomes.

Mesquita R, Vanfleteren LE, Franssen FM, Sarv J, Taib Z, Groenen MT, Gaffron S, Bruijnzeel PL, Pitta F, Wouters EF, Spruit MA.

Eur Respir J. 2015 Jun 25. pii: ERJ-00262-2015. doi: 10.1183/09031936.00026215. [Epub ahead of print] No abstract available.

PMID:
26113670
4.

Systemic manifestations of chronic obstructive pulmonary disease.

Warwick E, Scourfield A, Quint J.

Br J Hosp Med (Lond). 2015 Jun;76 Suppl 6:324-9. doi: 10.12968/hmed.2015.76.6.324.

PMID:
26053902
5.

The matrikine PGP as a potential biomarker in COPD.

Abdul Roda M, Fernstrand AM, Redegeld FA, Blalock JE, Gaggar A, Folkerts G.

Am J Physiol Lung Cell Mol Physiol. 2015 Jun 1;308(11):L1095-L1101. doi: 10.1152/ajplung.00040.2015. Epub 2015 Apr 10. Review.

PMID:
26033353
6.

COPD and squamous cell lung cancer: Aberrant inflammation and immunity is the common link.

Bozinovski S, Vlahos R, Anthony D, McQualter J, Anderson G, Irving L, Steinfort D.

Br J Pharmacol. 2015 May 25. doi: 10.1111/bph.13198. [Epub ahead of print]

PMID:
26013585
7.

Bacterial vaccines in chronic obstructive pulmonary disease: effects on clinical outcomes and cytokine levels.

Ruso S, Marco FM, Martínez-Carbonell JA, Carratalá JA.

APMIS. 2015 Jul;123(7):556-61. doi: 10.1111/apm.12386. Epub 2015 May 22.

PMID:
26010477
8.

Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management.

Woodruff PG, Agusti A, Roche N, Singh D, Martinez FJ.

Lancet. 2015 May 2;385(9979):1789-98. doi: 10.1016/S0140-6736(15)60693-6. Review.

PMID:
25943943
9.

Efficacy of indacaterol as a single therapy versus salmeterol/fluticasone therapy in patients with milder chronic obstructive pulmonary disease.

Ruxandra U, Antoniu SA, Mihaltan F, Boisteanu D.

Expert Opin Pharmacother. 2015 Jul;16(10):1539-41. doi: 10.1517/14656566.2015.1043888. Epub 2015 May 4.

PMID:
25936440
10.

Does this patient really have chronic obstructive pulmonary disease?

Hui S, How CH, Tee A.

Singapore Med J. 2015 Apr;56(4):194-6; quiz 197.

11.

COPD: early diagnosis and treatment to slow disease progression.

van der Molen T, Kirenga BJ.

Int J Clin Pract. 2015 May;69(5):513-4. doi: 10.1111/ijcp.12622. No abstract available.

PMID:
25913913
12.

Cardiovascular comorbidities in hospitalised COPD patients: a determinant of future risk?

Papaioannou AI, Bartziokas K, Loukides S, Tsikrika S, Karakontaki F, Haniotou A, Papiris S, Stolz D, Kostikas K.

Eur Respir J. 2015 Apr 16. pii: ERJ-02370-2014. doi: 10.1183/09031936.00237014. [Epub ahead of print] No abstract available.

PMID:
25882807
13.

Inflammation in the disease: mechanism and therapies 2014.

Seelaender M, Neto JC, Pimentel GD, Goldszmid RS, Lira FS.

Mediators Inflamm. 2015;2015:169852. doi: 10.1155/2015/169852. Epub 2015 Mar 24. No abstract available.

14.

Excess costs of comorbidities in chronic obstructive pulmonary disease: a systematic review.

Huber MB, Wacker ME, Vogelmeier CF, Leidl R.

PLoS One. 2015 Apr 13;10(4):e0123292. doi: 10.1371/journal.pone.0123292. eCollection 2015.

15.

Biological effects and mechanisms of action of mesenchymal stem cell therapy in chronic obstructive pulmonary disease.

Jin Z, Pan X, Zhou K, Bi H, Wang L, Yu L, Wang Q.

J Int Med Res. 2015 Jun;43(3):303-10. doi: 10.1177/0300060514568733. Epub 2015 Apr 1.

PMID:
25834280
16.

Preclinical murine models of Chronic Obstructive Pulmonary Disease.

Vlahos R, Bozinovski S.

Eur J Pharmacol. 2015 Jul 15;759:265-71. doi: 10.1016/j.ejphar.2015.03.029. Epub 2015 Mar 24.

PMID:
25818750
17.

Anemia in Chronic obstructive pulmonary disease: Prevalence, pathogenesis, and potential impact.

Sarkar M, Rajta PN, Khatana J.

Lung India. 2015 Mar-Apr;32(2):142-51. doi: 10.4103/0970-2113.152626. Review.

18.

[The diagnostic value of systemic inflammation biomarkers in chronic obstructive pulmonary disease].

Budnevskii AV, Ovsiannikov ES, Chernov AV, Drobysheva ES.

Klin Med (Mosk). 2014;92(9):16-21. Review. Russian.

PMID:
25790706
19.

Osteoporosis in chronic obstructive pulmonary disease.

Sarkar M, Bhardwaj R, Madabhavi I, Khatana J.

Clin Med Insights Circ Respir Pulm Med. 2015 Mar 12;9:5-21. doi: 10.4137/CCRPM.S22803. eCollection 2015. Review.

20.

A short-term mouse model that reproduces the immunopathological features of rhinovirus-induced exacerbation of COPD.

Singanayagam A, Glanville N, Walton RP, Aniscenko J, Pearson RM, Pinkerton JW, Horvat JC, Hansbro PM, Bartlett NW, Johnston SL.

Clin Sci (Lond). 2015 Aug 1;129(3):245-58. doi: 10.1042/CS20140654.

PMID:
25783022
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk